NK cell-based immunotherapy for cancer

Natural killer (NK) cells are a critical component of the innate immune system, capable of identifying and eliminating malignant cells without prior sensitization. Unlike T cells, which require specific antigen presentation, NK cells monitor for 'missing-self' signals—where tumor cells downregulate MHC class I molecules to evade T-cell detection—and 'stress-induced' signals triggered by cellular transformation. Despite this natural surveillance, tumors often evolve to suppress NK cell function or create immune-privileged environments, necessitating therapeutic intervention.

To harness NK cells for cancer treatment, researchers are exploring several adoptive transfer strategies. Autologous NK cell therapy, while safe, has historically yielded limited clinical success due to the inhibitory effects of self-MHC molecules and the immunosuppressive nature of the patient's own tumor environment. Consequently, the field has shifted toward allogeneic NK cell transfer, particularly using KIR-mismatched donors, which can trigger more potent anti-tumor responses. Additionally, the use of established NK cell lines, such as NK-92, offers a scalable and standardized platform for clinical-grade production, though these require careful quality control and safety monitoring.

To overcome the limitations of natural NK cells, researchers are employing genetic engineering to enhance their persistence and targeting. This includes modifying NK cells to express chimeric antigen receptors (CARs) that redirect them toward specific tumor antigens, or engineering them to overexpress cytokines like IL-15 to support survival and activation. Furthermore, combining NK cell therapy with monoclonal antibodies to leverage antibody-dependent cellular cytotoxicity (ADCC) or using non-invasive imaging to track NK cell accumulation in real-time are active areas of development. These advancements aim to transform NK cell therapy from a promising concept into a robust clinical tool for managing resistant malignancies.